SEER*Explorer Application

SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.

Read the full article here

Source: seer.cancer.gov

Categories: Onc News and Journals, General Medicine News

Tags: SoftTissueCancer,SarcomaAwarenessMonth

Tweets with this article

NCI Cancer Stats

The rate of new #SoftTissueCancer cases for men and women grew by 1.3% each year from 1975-2014 before falling by 2% each year from 2014-19. Visit SEER*Explorer to view more cancer statistics: https://t.co/ANRZCA8cR3 #SarcomaAwarenessMonth https://t.co/h2g99RHuNa

Cancer of the Stomach – Cancer Stat Facts

Stomach Cancer statistics

NCI Cancer Stats December 24, 2024

2024 Orphan Drugs: PDUFA Dates and FDA Approvals

Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…

CheckRare December 24, 2024

Conversations on Cancer

FDA Oncology December 24, 2024

Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

OncLive.com December 24, 2024

Expert Urges Researchers to Challenge Dogma & Forge Novel… : Oncology Times

An abstract is unavailable.

Oncology Times December 23, 2024

BET Inhibitor Shows Encouraging Safety and Tolerability in Myelofibrosis | Blood Cancers Today

The phase 1 study found that INCB057643, as monotherapy or in combination with ruxolitinib, was generally well tolerated in patients with relapsed or refractory MF.